Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neph-M Plus
- Development stage
- Unknown
- Lead developer
- Sapient Laboratories
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Neph-M Plus is an approved ophthalmic combination solution developed by Sapient Laboratories for the treatment of allergic eye diseases and temporary eye irritation, redness, and dryness. It is formulated as eye drops containing five active components: naphazoline (a decongestant), phenylephrine (a decongestant), hypromellose (a lubricant), camphor, and menthol (cooling agents). Naphazoline and phenylephrine act as alpha-adrenergic receptor agonists to constrict conjunctival blood vessels, thereby reducing redness and swelling. Hypromellose acts as an artificial tear lubricant to relieve dryness and burning, while camphor and menthol stimulate transient receptor potential (TRP) channels (such as TRPV3 and TRPM8) to provide a soothing, cooling sensation.
- Brand names
- Neph-M Plus
- Other names
- camphor + hydroxypropylmethylcellulose + menthol + naphazoline + phenylephrinecamphor + hypromellose + menthol + naphazoline + phenylephrineNeph-M Plus Eye DropNeph-M Plus Eye Drops
02
Targets
ADRA1A (α1A)ADRA2A (α2A)TRPM8 (Transient receptor potential cation channel subfamily M member 8)TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPV3 (Transient receptor potential vanilloid subtype 3)
Beyond the preview
Go deeper on Neph-M Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neph-M Plus.